1. Magnetic resonance imaging techniques for monitoring glioma response to chemoradiotherapy.
- Author
-
Lawrence LSP, Maralani PJ, Das S, Sahgal A, Stanisz GJ, and Lau AZ
- Abstract
Purpose: Treatment response assessment for gliomas currently uses changes in tumour size as measured with T
1 - and T2 -weighted MRI. However, changes in tumour size may occur many weeks after therapy completion and are confounded by radiation treatment effects. Advanced MRI techniques sensitive to tumour physiology may provide complementary information to evaluate tumour response at early timepoints during therapy. The objective of this review is to provide a summary of the history and current knowledge regarding advanced MRI techniques for early treatment response evaluation in glioma., Methods: The literature survey included perfusion MRI, diffusion-weighted imaging, quantitative magnetization transfer imaging, and chemical exchange transfer MRI. Select articles spanning the history of each technique as applied to treatment response evaluation in glioma were chosen. This report is a narrative review, not formally systematic., Results: Chemical exchange saturation transfer imaging potentially offers the earliest method to detect tumour response due to changes in metabolism. Diffusion-weighted imaging is sensitive to changes in tumour cellularity later during radiotherapy and is prognostic for progression-free and overall survival. Substantial evidence suggests that perfusion MRI can differentiate between tumour recurrence and treatment effect, but consensus regarding acquisition, processing, and interpretation is still lacking. Magnetization transfer imaging shows promise for detecting subtle white matter damage which could indicate tumour invasion, but more research in this area is needed., Conclusion: Advanced MRI techniques show potential for early treatment response assessment, but each technique alone lacks specificity. Multiparametric imaging may be necessary to aid biological interpretation and enable treatment guidance., Competing Interests: Declarations Ethical approval The studies used to generate the figures in this article were granted ethics approval by our institution’s Research Ethics Board. Consent to participate Written informed consent was obtain from all individual participants in the studies used for the figures in this article, including consent to publish anonymized data. Consent to publish See above. Competing interests LSPL has accepted travel expenses from Elekta. AS has research grants with Elekta, BrainLab, and Seagen Inc. He has been a consultant for Elekta and BrainLab. He has received honoraria for educational seminars from Elekta, Varian, BrainLab, AstraZeneca, Seagen Inc, Cerapedics, CarboFIX, and Servier. He has also accepted travel expenses from Elekta, BrainLab, and Cerapedics. He is the President of the International Stereotactic Radiosurgery Society (ISRS). SD serves as the Provincial Lead for CNS Cancers at Ontario Health (Cancer Care Ontario). He receives royalties from Oxford University Press and research funding from Synaptive, VPiX and Cure51. He is a speaker for the American Association of Neurological Surgeons and Congress of Neurological Surgeons and is on the advisory board of the Subcortical Surgery Group. PJM, GJS, and AZL have no relevant financial or non-financial interests to disclose., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF